Previous 10 | Next 10 |
PALO ALTO, Calif. , Aug. 6, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported financial results for second quarter 2020 and provided a bus...
PALO ALTO, Calif. , Aug. 3, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will participate in two upcoming investor confere...
The coronavirus pandemic has proved more difficult to contain in the US than was expected. I attribute this to the virus's contagion and virulence coupled with several states relaxing restrictions too early and to too great of an extent. As we try to forecast the course of events, several poss...
The pitfalls of vaccines After my earlier article , I thought I’d endorse my belief that antiviral combination therapy rather than vaccines will be the way to manage the COVID-19 pandemic. Recently, an FDA vaccine official suggested an increased vaccine “threshold” ...
PALO ALTO, Calif. , May 29, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) announced today that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders from federal, state and local authorities, and to support ...
PALO ALTO, Calif. , May 26, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that Eiger management will present a corporate update at the...
Eiger BioPharmaceuticals Receives FDA Acceptance of Zokinvy NDA Eiger BioPharmaceuticals, Inc. ( EIGR ) reported that the FDA has accepted its New Drug Application for accelerated review of Zokinvy (lonafarnib) for treating Progeria and Progeroid Laminopathies. The PDUFA for the drug has...
Under Priority Review status, the FDA accepts Eiger BioPharmaceuticals' (NASDAQ: EIGR ) marketing application seeking approval of Zokinvy (lonafarnib) for the treatment of progeria and progeroid laminopathies, a rare inherited disorder characterized by rapid aging (most children do not l...
PALO ALTO, Calif. , May 19, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration (FDA) a...
Eiger BioPharmaceuticals ( EIGR ) is developing lonafarnib, an oral prenylation inhibitor, to treat Hepatitis D and Progeria. Hepatitis D is typically a superinfection on top of Hepatitis B, leading to a more severe form of the disease. It affects 15-20 million people worldwide, and there is n...
News, Short Squeeze, Breakout and More Instantly...
Eiger BioPharmaceuticals Inc. Company Name:
EIGR Stock Symbol:
NASDAQ Market:
Eiger BioPharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 6.5% to $0.95 on volume of 182,734,103 shares WiSA Technologies Inc. (WISA) fell 3.3% to $0.0235 on volume of 160,634,740 shares PROSHARES TRUST (SQQQ) rose 4.7% to $11.12 on volume of 151,373,755 shares...
A look at the top 10 most actives in the United States Sunshine Biopharma Inc. (SBFM) rose 76.0% to $0.1065 on volume of 290,483,542 shares CXApp Inc. (CXAI) rose 151.0% to $6.15 on volume of 236,739,031 shares Nikola Corporation (NKLA) fell 1.0% to $1.03 on volume of 123,276,764 shares ...
Announces “Stalking Horse” Agreement for the Sale of Zokinvy ® (lonafarnib) Patient Access to Zokinvy ® to Continue Uninterrupted PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today ...